GH Research PLC (GHRS)vsModerna Inc (MRNA)
GHRS
GH Research PLC
$28.65
-1.24%
HEALTHCARE · Cap: $2.05B
MRNA
Moderna Inc
$142.77
-4.60%
HEALTHCARE · Cap: $57.00B
Smart Verdict
WallStSmart Research — data-driven comparison
GHRS leads profitability with a 0.0% profit margin vs -141.4%. GHRS earns a higher WallStSmart Score of 25/100 (F).
GHRS
Avoid25
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GHRS.
Margin of Safety
+70.0%
Fair Value
$135.25
Current Price
$142.77
$7.52 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Trading at 8.4x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : GHRS
The strongest argument for GHRS centers on Debt/Equity, Altman Z-Score.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : GHRS
The primary concerns for GHRS are Revenue Growth, EPS Growth, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
GHRS profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
GHRS carries more volatility with a beta of 1.29 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
GHRS generates stronger free cash flow (-15M), providing more financial flexibility.
Bottom Line
GHRS scores higher overall (25/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GH Research PLC
HEALTHCARE · BIOTECHNOLOGY · USA
GH Research PLC is a pioneering clinical-stage biopharmaceutical company focused on developing psilocybin-based therapies for psychiatric and neurodegenerative disorders. The company's robust pipeline addresses critical unmet needs in mental health treatment, underscored by a commitment to innovative therapeutic solutions led by a seasoned management team. By harnessing its proprietary scientific approach, GH Research is strategically positioned to disrupt current treatment paradigms and enhance patient outcomes, establishing itself as a prospective leader in the rapidly evolving mental health therapeutics sector.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?